Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Robert S. Epstein"'
Autor:
Robert S. Epstein, Robert R. Verbrugge, Lawrence J. Lesko, Gilbert J. Burckart, Teresa M. DeLuca, Felix W. Frueh, Ronald E. Aubert, Padmaja Mummaneni, Shashi Amur
Publikováno v:
Pharmacotherapy. 28:992-998
Study Objectives. To review the labels of United States Food and Drug Administration (FDA)-approved drugs to identify those that contain pharmacogenomic biomarker information, and to collect prevalence information on the use of those drugs for which
Autor:
Laurie Kamimoto, Jianying Yao, Robert S. Epstein, Joseph S. Bresee, David K. Shay, Ronald E. Aubert, Justin R. Ortiz
Publikováno v:
Emerging Infectious Diseases
We reviewed information from a US pharmacy benefits manager database from 2004 through 2005 during periods with little influenza activity. We calculated rates of oseltamivir prescriptions to enrollees. Prescription rates increased significantly from
Autor:
Robert S. Epstein, Becky Nagle, Calvin Wasdyke, Patrick M.S. Courtney, J. Russell Teagarden, Ronald E. Aubert
Publikováno v:
Pharmacotherapy. 25:1629-1635
Study Objective. To measure the rate of dispensing errors and to identify the types and sources of dispensing errors in a highly automated mail-service pharmacy practice. Design. Descriptive analysis of a random sample of completed prescriptions. Set
Publikováno v:
Value in Health. 1(4):233-236
Lipid-lowering therapy can account for 7% of per patient per month drug costs. Because this can be a significant proportion of a payer's drug expenditure, this class of drugs attracts payers' attention and thus becomes a focus of efforts designed to
Autor:
Robert S. Epstein
Publikováno v:
Clinical pharmacology and therapeutics. 88(6)
Over the years, pharmacy benefit managers (PBMs) have conducted and published peer-reviewed research covering a broad spectrum of activities ranging from studying the impact of alternative-benefit designs on outcomes to identifying the epidemiology o
Autor:
Felix W. Frueh, Jianying Yao, Ronald E. Aubert, C. Sanders, Robert S. Epstein, Eric J. Stanek
Publikováno v:
Journal of Clinical Oncology. 27:7077-7077
7077 Background: Recommendations for baseline and quarterly measurement of the BCR-ABL fusion transcript to monitor imatinib response in patients with chronic myelogenous leukemia (CML) were formally introduced in October 2006, and have been incorpor
Publikováno v:
Drug Information Journal. 31:1405-1405